Friends of Cancer Research

GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population

Retrieved on: 
Monday, November 20, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Health Technology, Clinical Trials, MSHS, Woman, Health equity, Medicaid, Safety, Food, National Medical Association, NMA, Randomized controlled trial, Risk, Patient, Multimedia, ASCO, Friends of Cancer Research, Death, FDA, CMS, IDE, Friends, MD, Diagnosis, Partnership, 123rd, Medicare, PMA, Human, Pharmaceutical industry, Health insurance, Dietary supplement, Lancet, GRAIL, Cancer

With age being the most significant risk factor for cancer, Medicare beneficiaries face the highest unmet need for early cancer detection.

Key Points: 
  • With age being the most significant risk factor for cancer, Medicare beneficiaries face the highest unmet need for early cancer detection.
  • View the full release here: https://www.businesswire.com/news/home/20231120057874/en/
    The Galleri-Medicare study is a first-of-its-kind real-world study designed to further evaluate the clinical impact of the Galleri® multi-cancer early detection (MCED) test among Medicare beneficiaries, including racial and ethnic minorities, and seniors from historically under-served communities.
  • Medicare will cover the costs of Galleri and related and routine items and services for study participants.
  • “The Galleri-Medicare study demonstrates our commitment to provide broad, equitable access to early cancer detection that is representative of the U.S. population, including groups that are often under-represented in clinical research.

City of Hope Vice Physician-in-Chief Edward S. Kim, M.D., M.B.A, Recognized as a Top Diversity Leader in U.S. Healthcare

Retrieved on: 
Monday, November 6, 2023
Oncology, Professional Services, DEI (Diversity, Equity and Inclusion), Health, Clinical Trials, Research, Science, Faculty, Policy, Modern Healthcare, Friends, American Society of Clinical Oncology, City of Hope, Cancer Prevention Research, Lung cancer, Physician, Friends of Cancer Research, Head, State, Organization, The Lancet, Journal, Society, Multimedia, Quality of life, City, Lung, Clinical trial, Diversity, Journal of Clinical Oncology, Cancer Discovery (journal), Patient, ASCO, National Integration Party (Costa Rica), Nature Medicine, Pharmaceutical industry, Hospital, Nursing, Medical imaging, Hope, Cancer, Lancet

City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .
  • The prestigious honor recognizes diverse health care executives and organizations influencing policy and care delivery across the country.
  • This is the second time Kim — a renowned lung cancer expert and physician-executive — has earned this recognition.
  • “Ed is deeply committed to ensuring that everyone we serve has equitable access to advanced cancer care,” said Annette Walker, president, City of Hope Orange County.

Beaconcure Technologies Welcomes Additions to Leadership Team

Retrieved on: 
Tuesday, October 3, 2023
Technology, Biotechnology, FDA, Health, Pharmaceutical, Artificial Intelligence, Other Science, Research, Software, Networks, Health Technology, Science, Data Management, Clinical Trials, GSK plc, Software as a service, Partnership, Central Waqf Council, Senior, Marketing, LLM, Bill & Melinda Gates Foundation, Clinical trial, Information science, MBA, CMO, History, Doctor of Philosophy, AstraZeneca, Organization, Friends, Neuroscience, Dermatology, Biometrics, COVID-19, MD, Patient, Celebrity board director, Commercial, Friends of Cancer Research, Rare, CDISC, Cardiology, Biostatistics, Enterprise data planning, Automation, Data science, Management, Pharmaceutical industry

Beaconcure Technologies , a leader in AI-enabled clinical data validation and automation, announces enhancements to its leadership team, emphasizing its dedication to innovation in drug delivery and clinical data science.

Key Points: 
  • Beaconcure Technologies , a leader in AI-enabled clinical data validation and automation, announces enhancements to its leadership team, emphasizing its dedication to innovation in drug delivery and clinical data science.
  • Beaconcure is pleased to introduce the following professionals who have joined their Strategic Advisory Board and Commercial Leadership teams:
    Dr. Karen Smith , MD, PhD, MBA, LLM: Dr. Smith, a distinguished biotech and pharmaceutical executive, has joined Beaconcure's Strategic Advisory Board.
  • Beaconcure CEO and co-founder Yoran Bar comments on the significance of these appointments, highlighting their dedication to healthcare innovation.
  • Yoran Bar remarked, "Welcoming Dr. Karen Smith, Névine Zariffa, and Sean Wall to our vibrant team marks a monumental milestone for Beaconcure Technologies.

THERESA'S RESEARCH FOUNDATION ANNOUNCES NEW WHITE PAPER AND CELEBRATES 10 YEARS OF BRINGING CANCER RESEARCHERS AND PATIENT ADVOCATES TOGETHER

Retrieved on: 
Monday, August 21, 2023
Steps, Linda, Mayo Clinic, University, Education, Friends, Accidental Death and Disability: The Neglected Disease of Modern Society, White paper, Johns Hopkins School of Medicine, Metastatic breast cancer, Cancer, Research, Doctor of Philosophy, Alvin J. Siteman Cancer Center, University of Utah, Basic research, Huntsman Cancer Institute, Professor, Patient, Breast cancer, Baylor College of Medicine, Odds, Friends of Cancer Research, Family, Conference, Nursing, Birth control, Pharmaceutical industry

This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .

Key Points: 
  • This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .
  • "Patient advocates and cancer researchers working together is critical for better research that leads to improved patient outcomes.
  • "I'm thrilled to welcome so many outstanding breast cancer researchers from across the world to the 10th annual Metastatic Breast Cancer Research Conference.
  • The Foundation will host a celebration to mark its 10-year milestone at this year's Metastatic Breast Cancer Research Conference in Park City, Utah on August 31.

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Abstract, DNA, Circulating tumor DNA, Drug development, ICI, Classification, HIC, Lung cancer, Prescription, NSCLC, Government, ASCO, Organization, Friends, Data analysis, American Society of Clinical Oncology, Patient, Annual general meeting, Diagnosis, Poster, Friends of Cancer Research, Neoplasm, Society, Medical imaging, Medical device

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.
  • The new data release indicates that ctDNA shows promise as an early endpoint to support drug development and regulatory decision-making.
  • “We are thrilled to partner with our colleagues in industry, academia, government and Friends of Cancer Research in contributing to the new data analysis on ctDNA and outcomes that will be released at the ASCO 2023 Annual Meeting,” said Gary Pestano, Chief Development Officer of Biodesix.
  • These analyses evaluated healthcare resource utilization (HCRU) and healthcare costs in patients with non-small cell lung cancer (NSCLC) classified by the test.

COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

Retrieved on: 
Tuesday, January 31, 2023
Software, Research, Networks, Pharmaceutical, Oncology, Data Management, Technology, Health Technology, Clinical Trials, Science, Biotechnology, Health, Organization, Trust, CRDSA, Drug development, University of Texas Southwestern Medical Center, Patient, Clinical trial, University, Food, Friends of Cancer Research, Privacy, University of Rochester, Lung cancer, Friends, Georgetown Lombardi Comprehensive Cancer Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NSCLC, Cancer, Pharmaceutical industry

COTA, Inc. , an oncology real-world data and analytics company, today announced its membership in the Clinical Research Data Sharing Alliance (CRDSA), a nonprofit, cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service and technology partners.

Key Points: 
  • COTA, Inc. , an oncology real-world data and analytics company, today announced its membership in the Clinical Research Data Sharing Alliance (CRDSA), a nonprofit, cross-industry alliance of biopharma companies, data sharing platforms, academic institutions, and service and technology partners.
  • Member organizations collaborate to accelerate the discovery and delivery of life-saving therapies to patients through the use of high-quality clinical trial and real-world data.
  • As the newest member of CRDSA, COTA will participate in the Alliance’s steering committee and the Innovative Trial Design Working Group.
  • One of the goals of this project is to explore the complementary use of real-world and clinical trial data in research and drug development.

Aetion Leads Cross Industry Initiative to Understand Strengths and Limitations of Regulatory Use of Real-World Evidence

Retrieved on: 
Tuesday, November 29, 2022
Real-World Evidence, COVID-19, AstraZeneca, Public health, Friends, Hospital, AbbVie, Multimedia, Harvard Medical School, Safety, Real world evidence, Friends of Cancer Research, Health, Initiative, Coalition, Isabella Tree, Reagan-Udall Foundation, Aetion, Cone Health Women's Hospital, Epidemiology, RWE, Baylor College of Medicine, Health policy, CARE, RCT, Pharmaceutical industry, Bayer, Brigham, Tempus, Pfizer

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. The first phase of the Initiative will focus on oncology and involves a group of diverse partners including AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women's Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, and xCures.

Key Points: 
  • Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.
  • "Data quality, accessibility, and analytical tools are progressing at a rapid pace," said Carolyn Magill, Chief Executive Officer at Aetion.
  • "We and our partners launched the Aetion CARE Initiative to advance global alignment on scientific methodologies to create real-world evidence and aid in its interpretation."
  • Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies.

Aetion Leads Cross Industry Initiative to Understand Strengths and Limitations of Regulatory Use of Real-World Evidence

Retrieved on: 
Tuesday, November 29, 2022
Real-World Evidence, COVID-19, AstraZeneca, Public health, Friends, Hospital, AbbVie, Harvard Medical School, Safety, Real world evidence, Friends of Cancer Research, Health, Initiative, Coalition, Isabella Tree, Reagan-Udall Foundation, Aetion, Cone Health Women's Hospital, Epidemiology, RWE, Baylor College of Medicine, Health policy, CARE, RCT, Pharmaceutical industry, Bayer, Brigham, Tempus, Pfizer

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. The first phase of the Initiative will focus on oncology and involves a group of diverse partners including AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women's Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, and xCures.

Key Points: 
  • Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.
  • "Data quality, accessibility, and analytical tools are progressing at a rapid pace," said Carolyn Magill, Chief Executive Officer at Aetion.
  • "We and our partners launched the Aetion CARE Initiative to advance global alignment on scientific methodologies to create real-world evidence and aid in its interpretation."
  • Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies.

Dr. David Gerber, University of Texas Southwestern, and LUNGevity Foundation Publish Recommendations to Simplify and Harmonize Lung Cancer Clinical Trials

Retrieved on: 
Tuesday, August 30, 2022
Strathcona County, Lung cancer, Johns Hopkins University, Helpline, MPH, Criterion, National Cancer Institute, American Society of Clinical Oncology, Friends, The Heritage Foundation, Research, Health equity, Caregiver, Survival, University of Texas Southwestern Medical Center, Smoker, Doctor of Philosophy, Paper, Friends of Cancer Research, Review, Quality of life, JAMA Oncology, Foundation, Multimedia, BUT, Manuscript, MD, Human, Clinical trial, Conference, Publication, FDA, Cancer, Language, Science, National, Charity Navigator, Patient, Public policy, Pharmaceutical industry, Medical imaging

WASHINGTON, Aug. 30, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, convened a team of oncology thought leaders, the United States Food and Drug Administration, the National Cancer Institute, and industry sponsors to develop recommendations for a framework for lung cancer clinical trial eligibility criteria. The eligibility template recommendations, published recently in JAMA Oncology, will help simplify eligibility criteria and make searching for and comparing clinical trials easier for patients and clinicians.

Key Points: 
  • The eligibility template recommendations, published recently in JAMA Oncology , will help simplify eligibility criteria and make searching for and comparing clinical trials easier for patients and clinicians.
  • "When patients are looking for a clinical trial to consider participating in, the eligibility criteria are often confusing and difficult to navigate.
  • "Through previous publications, the Foundation has advocated for expanding eligibility criteria and removing restrictive eligibility in lung cancer clinical trials to increase the number of patients able to access livesaving therapies in clinical development.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

Manuscript for Improving Cancer Scientist and Patient Advocate Relationships Published

Retrieved on: 
Thursday, June 30, 2022
Baylor University, Baylor College of Medicine, Patient, Science, Breast cancer, Research, Huntsman Cancer Institute, Cancer, Goal, Professor, Hope, Basic research, Odds, Breast, University, Doctor of Philosophy, Quality of life, Friends, Solution, GRASP, Metastatic breast cancer, Manuscript, Friends of Cancer Research, Conference, Dietary supplement, Pharmaceutical industry, Medicine

HOUSTON, June 30, 2022 /PRNewswire/ -- Theresa's Research Foundation is excited to announce a new manuscript titled " Improving the Odds Together: A Framework for Breast Cancer Research Scientists to Include Patient Advocates in their Research " published today in npj Breast.

Key Points: 
  • HOUSTON, June 30, 2022 /PRNewswire/ -- Theresa's Research Foundation is excited to announce a new manuscript titled " Improving the Odds Together: A Framework for Breast Cancer Research Scientists to Include Patient Advocates in their Research " published today in npj Breast.
  • An appreciation for the value of including the patient advocate voice in cancer research has increased in recent years, however, basic research scientists are often uncertain about how to establish or maintain relationships with advocates.
  • "When scientists partner with patient advocates, real experiences of people living with cancer inform the work at every step, rather than being an afterthought.
  • Our hope is that the findings in the manuscript will encourage more basic research scientists to work with patient advocates to improve cancer research and patient outcomes," said Hillary Stires, PhD, Science Policy Analyst at Friends of Cancer Research.